Treatment of ischemic ulcers of the lower limbs with alprostadil (prostaglandin E1)

Dermatologic Surgery

Volumn 30, Issue 8, 2004, Pages 1113-1117

  Tondi, Paolo ^a   Gerardino, Laura ^a   Santoliquido, Angelo ^a   Pola, Roberto ^a   Gabrielli, Maurizio ^a   Papaleo, Pierangelo ^a   Gasbarrini, Antonio ^a   Pola, Paolo ^a   Flore, Roberto ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E1; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; OXYGEN TENSION; PAIN ASSESSMENT; PRIORITY JOURNAL; PULSE OXIMETRY; SIDE EFFECT; STATISTICAL ANALYSIS; TRANSCUTANEOUS OXYGEN MONITORING; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALPROSTADIL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEG ULCER; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 4344626021     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30336.x     Document Type: Article

References (18)

1. Verstraete M, Verhaeghe R. Primary pharmacotherapy other than prostanoids. In: Dormandy JA, Stock J, eds. Critical Leg Ischaemia - Its Pathophysiology and Management. Berlin: Springer-Verlag, 1990:99-113.
2. Critical ischemia of the limbs. Consensus meeting of the European Working Group on Critical Leg Ischaemia 9-11 March 1989. Klin Wochenshr 1989;67(Suppl 14):1-16.
3. Akesson H, Bjellerup M. Leg ulcers: report on a multidisciplinary approach. Acta Derm Venereol 1995;75:133-5.
4. 2. Naunyn-Schmiedeberg's Arch Pharmacol 1990;341:308-15.
5. Fantone JC, Kunkkel SL, Ward PA, Zurier RB. Suppression of human polimorphonuclear leukocyte function after intravenous infusion of prostaglandine E1. Prostaglandins Med 1981;2:195-8.
6. Mangiafico RA, Malatino LS, Attina T, Dell'Arte S, Messina R. Effects of infusion treatment once a day for 4 weeks with alprostadil-alpha-ciclodextrin on blood levels of endothelin-1 in patients with chronic obliterative arteriopathy of the legs at Leriche-Fontaine stage 2. Minerva Cardioangiol 1999;47:652-3.
7. Crutchley DJ, Conan LB, Maynard JR. Stimulation of fibrynolitic activity in human skin fibroblast by prostaglandins E1, E2 and I2. J Pharmacol Exp Ther 1982;222:544-9.
8. Alstaedt HO, Berzewski B, Breddin HK. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous Iloprost and PGE1: a randomized open controlled study. Prostaglandins-Leukot- Essent-Fatty-Acids 1993;49:573-8.
9. Pola P, Tondi P, Serricchio M, Favuzzi A, Gerardino L. New prospect for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin (iloprost). Angiology 1993;44:123-8.
10. Gerardino L, Santoliquido A, Flore R, et al. Efficacy of iloprost in nonexudative, age-related macular degeneration. J Am Geriatr Soc 2000;48:1350-1.
11. Rudofsky G. The effect of intrarterial and intravenous prostaglandin El in a model of ischaemia in healthy volunteers. In: Sinzingher H, Rogatti W, eds. Prostaglandin El in Atherosclerosis. Berlin: Springer-Verlag, 1986:49-53.
12. Rexroth W, Amendt K, Rommele U, et al. Effekte von prostaglandin El auf haemodynamic und extremitatenstoffwechsel bei gesunden und pazienten mit arterieller verschlusskrankheit stadium III und IV. Vasa 1985;14:220-4.
13. Kruse HJ, Shellong S. Prostaglandin therapy in arterial occlusive disease. Dtsch Med Wochenschr 2001;126:315-6.
14. Bianchi J, Douglas WS, Dawe RS, et al. Pulse oximetry: a new tool to assess patients with leg ulcers. J Wound Care 2000;9:109-12.
15. Pola P, Tondi P, Dal Lago A, et al. Transcutaneous oxirnetry is useful in vascular pathology if a cutaneous reference map and a maximal exercise test are used. Vasc Surg 1996;30:117-22.
16. Schermerhorn ML, Cronenwett JL, Baldwin JC. Open surgical repair versus endovascular therapy for chronic lower-extremity occlusive disease. Annu Rev Med 2003;54:269-83.
17. Peripheral Arterial Disease Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease: consensus statement. Eur J Vasc Endovasc Surg 2003;26:1-16.
18. Bounameaux H, Wutschert R. Drug treatment strategies for peripheral obliterative arteriopathy. Drugs 1998; (Suppl 3):17-23.